mRECIST outcomes in EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with or without bevacizumab in participants with embolization-eligible hepatocellular carcinoma Meeting Abstract
| Authors: | Sangro, B.; Kudo, M.; Erinjeri, J. P.; Qin, S.; Ren, Z.; Chan, S.; Arai, Y.; Heo, J.; Mai, A.; Penagos, F. E.; Chuken, Y. A. L.; Yoon, J. H.; Tak, W. Y.; Suttichaimongkol, T.; Bouattour, M.; Lin, S. M.; Zotkiewicz, M.; Ai, S.; Cohen, G. J.; Lencioni, R. |
| Abstract Title: | mRECIST outcomes in EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with or without bevacizumab in participants with embolization-eligible hepatocellular carcinoma |
| Meeting Title: | 66th Annual Meeting of the American Society for Radiation Oncology (ASTRO 2024) |
| Journal Title: | International Journal of Radiation Oncology, Biology, Physics |
| Volume: | 120 |
| Issue: | 2 Suppl. |
| Meeting Dates: | 2024 Sep 29-Oct 2 |
| Meeting Location: | Washington, DC |
| ISSN: | 0360-3016 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2024-10-01 |
| Start Page: | e438 |
| End Page: | e439 |
| Language: | English |
| ACCESSION: | WOS:001325892301305 |
| PROVIDER: | wos |
| DOI: | 10.1016/j.ijrobp.2024.07.977 |
| Notes: | Meeting Abstract: 2973 -- Source: Wos |
